 This is an open label single site Phase II clinical trial to identify a potentially promising therapy dose for Sunitinib malate, an oral multi-kinase inhibitor. The study drug will be taken orally once daily on days 1 through 28 of each 42 day cycle. Treatment will be continued until there is either disease progression or cumulativeacute toxicity which in the opinion of the treating physician or the trial Principal Investigator PI compromises the ability of the patient to receive treatment or the patient desires to stop treatment. 